|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Is autoimmune hepatitis a frequent finding among HCV patients with intense interface hepatitis?显示文摘AIM:To evaluate the overlap of autoimmune hepatitis in hepatitis C virus(HCV)-infected patients with intense interface hepatitis.METHODS:Among 1759 patients with hepatitis C submitted to liver biopsy,92(5.2%) presented intense interface hepatitis.These patients were evaluated regarding the presence of antinuclear antibody(ANA),anti-smooth muscle antibody(SMA) and anti-liver/kidney microsomal antibody(LKM-1),levels of γ-globulin and histological findings related to autoimmune hepatitis(plasma cell infiltrate and presence of rosettes).RESULTS:Among patients with hepatitis C and intense interface hepatitis there was a low prevalence of autoantibodies(ANA=12%,SMA=5%,LKM-1=0%) and the median γ-globulin level was within the normal range.Typical histological findings of autoimmune disease were observed in only two cases(2%).After applying the score for diagnosis of autoimmune hepatitis,only one patient was classified with a definitive diagnosis of autoimmune hepatitis.Since overlap with autoimmune hepatitis was not the explanation for the intense necroinflammatory activity in patients with chronic hepatitis C we sought to identify the variables associated with this finding.The presence of intense interface hepatitis was associated with more advanced age,both at the time of infection and at the time of the biopsy,and higher prevalence of blood transfusion and alcohol abuse.CONCLUSION:Although possible,overlap with autoimmune hepatitis is a very rare association in HCV-infected patients with intense interface hepatitis,an unusual presentation which seems to be related to other host variables. | Rosilene G Badiani Vitória Becker Renata M Perez Carla AL Matos Lara B Lemos Valéria P Lanzoni Luis Eduardo C Andrade Alessandra Dellavance Antonio Eduardo B Silva Maria Lucia G Ferraz | 2010 | World Journal of Gastroenterology2010，16，29： | 7 |
| 2 | N-acetyl-L-cysteine combined with mesalamine in the treatment of ulcerative colitis: Randomized,placebo-controlled pilot study显示文摘AIM: To evaluate the effectiveness and safety of oral N-acetyl-L-cysteine (NAC) co-administration with mesalamine in ulcerative colitis (UC) patients. METHODS: Thirty seven patients with mild to moderate UC were randomized to receive a four-wk course of oral mesalamine (2.4 g/d) plus N-acetyl-L-cysteine (0.8 g/d) (group A) or mesalamine plus placebo (group B). Patients were monitored using the Modified Truelove-Witts Severity Index (MTWSI). The primary endpoint was clinical remission (MTWSI ≤ 2) at 4 wk. Secondary endpoints were clinical response (defined as a reduction from baseline in the MTWSI of ≥ 2 points) and drug safety. The serum TNF-α, interleukin-6, interleukin-8 and MCP-1 were evaluated at baseline and at 4 wk of treatment. RESULTS: Analysis per-protocol criteria showed clinical remission rates of 63% and 50% after 4 wk treatment with mesalamine plus N-acetyl-L-cysteine (group A) and mesalamine plus placebo (group B) respectively (OR = 1.71; 95% CI: 0.46 to 6.36; P = 0.19; NNT = 7.7). Analysis of variance (ANOVA) of data indicated a significant reduction of MTWSI in group A (P = 0.046) with respect to basal condition without significant changes in the group B (P = 0.735) during treatment. Clinical responses were 66% (group A) vs 44% (group B) after 4 wk of treatment (OR = 2.5; 95% CI: 0.64 to 9.65; P = 0.11; NNT = 4.5). Clinical improvement in group A correlated with a decrease of IL-8 and MCP-1. Rates of adverse events did not differ significantly between both groups. CONCLUSION: In group A (oral NAC combined with mesalamine) contrarily to group B (mesalamine alone), the clinical improvement correlates with a decrease of chemokines such as MCP-1 and IL-8. NAC addition not produced any side effects. | Luis G Guijarro Jose Mate Javier P Gisbert Jose Luis Perez-Calle Ignacio Marín-Jimenez Encarna Arriaza Tomás Olleros Mario Delgado Maria S Castillejo David Prieto-Merino Venancio Gonzalez Lara Amado Salvador Pea | 2008 | World Journal of Gastroenterology2008，14，18： | 2 |
| 3 | The role of squamous cell carcinoma antigen in the management of laryngeal and hypopharyngeal cancer显示文摘 | Lara P C Cuyas J M | 1995 | Cancer1995，76，5： | 1 |
| 4 | Potential application of waste activated bleaching earth on the production of fatty acid alkyl esters using Candida cylindracea lipase in organic solvent system 显示文摘 | LARA P V PARK E Y | 2004 | Enzyme Microb Tech2004，34，34： | 1 |
| 5 | Phase Ⅱ trial of irinote-ean/cisplatin compared with etoposide/cisplatin in extersive-stage small-cen lung cancer:clinical and pharmarogenomic results from SWOG SO124 显示文摘 | Lara P N Jr Natale R Crouley J | 2009 | J Clin Onco12009，27，15： | 1 |
| 6 | Potential application of waste activated bleaching earth on the production of fatty acid alkyl esters using Candida cylindracea lipase in organic solvent system显示文摘 | LARA P V PARK E Y | 2004 | Enzyme and Microbial Technology2004，34，34： | 1 |
| 7 | Mamey sapote cultivars in Florida显示文摘 | Campbell C W S P Lara | 1982 | Processdings of the Florida State Horticultural Society1982，95，： | 1 |
| 8 | 显示文摘 | Lara Wilfredo C Jeremy S Lewis Rodney P | 1998 | Journal of Long-Term Effects of Medical Implants1998，8，1： | 1 |
| 9 | Relationship between organizational justice and cyberloafing in the workplace: has ' Anomia' a say in the matter? 显示文摘 | De Lara M Zoghbi P | 2007 | CyberPsyehology & Behavior2007，10，3： | 1 |
| 10 | Gemcitabine and plantinum combination in advanced non-small cell lung cancer :An update 显示文摘 | Candra DR Edelman MJ Lara P | 2000 | Lung Cancer2000，29，2： | 1 |
| 11 | Activity of highdose toremifene plus eispLatin in platinum-treated nonsmall-cell lung cancer:,a phase Ⅱ California Cancer Consortium Trial显示文摘 | Lara P Jr Gandara DR Longmate J | 2001 | Cancer Chemother Pharmacol2001，48，1： | 1 |
| 12 | Phase III trial of irinotecan/cisplatin compared with etoposide/cisplatin in extensive - stage small - cell lung cancer: clinical and pharmacogenomic results from SWOG S0124 显示文摘 | Lara P N Jr Natale R Crowley J | 2009 | J Clin Oncol2009，27，15： | 1 |
| 13 | General spin Ising model with random crystal field in the pair approximation 显示文摘 | PLASCAK J A | 1998 | Physica A1998，260，： | 1 |
| 14 | Potential application of waste activated bleaching earth on the production of fatty acid alkyl esters using Candida cylindracea lipase in organic solvent system显示文摘 | Lara P V Park E Y | 2004 | Enzyme and Microbial Technology2004，34，34： | 1 |
| 15 | Resorbable synthetic mesh supported with omentum flap in the treatment of giant hiatal hernia显示文摘 | Pérez Lara FJ Marín R del Rey A | 2014 | Int Surg2014，99，5： | 1 |
| 16 | Polybrominated diphenyl ether in theEast Asian environment: A critical review显示文摘 | Wang Y Jiang G Lara P K S | 2007 | Environmental Internalion-ai2007，33，： | 1 |
| 17 | Neoadjuvant Therapy for Non-Small Cell Lung Cancer显示文摘 | Gandara D R Lara P Goldberg Z | 2001 | Anticancer drugs2001，12，1： | 1 |
| 18 | A simple method for real-time DSP-based neutron-chopper speed and phase control显示文摘 | ROSE C R LARA P D NELSON R O | 2001 | Proceedings of the Particle Accelera- tor Conference2001，，： | 1 |
| 19 | A randomized phase Ⅱ trial of the matrix metalloproteinase inhibitor BMS-275291 in hormone-refractory prostate cancer patients with bone metastases显示文摘 | LARA P N STADLER W M LONGMATE J | 2006 | Clin Cancer Res2006，12，5： | 1 |
| 20 | Potential application of waste activated bleaching earth on the production of fatty acid alkyl esters using Candida cylindracea lipase in organic solvent system显示文摘 | LARA P V PARK E Y | 2004 | Enzyme and Microbial Technology2004，34，： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员